# Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

> **NCT00811889** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 227 (actual)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes
- Diabetic Nephropathy

## Interventions

- **OTHER:** Placebo
- **DRUG:** Bardoxolone Methyl (RTA 402)

## Key facts

- **NCT ID:** NCT00811889
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-30
- **Primary completion:** 2010-05-31
- **Final completion:** 2010-12-31
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00811889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00811889, "Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00811889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*